At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,205 enrolled
Drug / intervention
Eravacycline +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
In Brief
A Phase 3 clinical trial evaluating Eravacycline, Ertapenem, and 2 other interventions for Complicated Urinary Tract Infections. Completed, enrolled 1,205 participants across 69 sites in 12 countries.
Detailed Summary
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComplicated Urinary Tract Infections
CountriesAustria, Bulgaria, Estonia, Georgia, Hungary, Latvia, Moldova, Romania, Russia, Slovakia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJan 2017
Primary CompletionDec 2017
Study CompletionJan 2018
TodayJul 2026
First PostedJan 26, 2017
Enrollment StartJan 1, 2017
Primary CompletionDec 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.4 years ago
Interventions
Eravacyclinedrug
Ertapenemdrug
Placebodrug
Levofloxacindrug